Citations

Clear

410 citation(s) found for "Shu, Yu".

Abstract WP112: Predictors of 90-Day Recurrent Stroke in Patients with High-Grade Intracranial Atherosclerotic Stenosis: A subgroup analysis from the BIORISK-ICAS Study
Stretz, Christoph, Lewis, Skylar, Chahien, Dalia, Alam, Shaista , Halabi, Tarek El, Guerrero, Chris, Walsh, Hadley A., Frontera, Jennifer, baker, rich, Nguyen, Thanh, Tunguturi, Ajay, Khan, Muhib, Klaas, James P. , Liebeskind, D, Morsi, Rami, Helenius, Johanna, Khatri, Pooja, Freitas, Joao, Aziz, Yasmin, Rothstein, Aaron, Shu, Liqi , Reda, Mahasen, Tountopoulou, Argyro , Khasawneh, Mohammad W , Klein, Piers, Havenon, Adam de, Almiri, William , Prabhakaran, S, AlMajali, Mohammad, Zaidat, Osama, Qdais, Ahmad Abu, McCullough-Hicks, Margy, Elangovan, Cheran, Sousa, João André, Romoli, Michele, Henninger, Nils, Marto, Joao Pedro, Agarwal, Ayush, Kasab, Sami Al, Yaddanapudi, Sridhara , Krishnaiah, Balaji , Sousa, Diana Aguiar de, Yaghi, Shadi, Henninger, Nils , Sousa, Diana Aguiar de , Henninger, Nils , Aguiar de Sousa, Diana , Khan, Fahad , Stretz, Christoph , Alam, Shaista, Halabi, Tarek El , Sloane, Kelly L , Heldner, Mirjam R. , Antonenko, Kateryna , Baker, Richard, Khan, Muhib , Marrone, Nicole L. , Siegler, James E. , Morsi, Rami Z. , Aziz, Yasmin , Rothstein, Aaron , Reda, Mahasen , Prabhakaran, Shyam , McCullough‐Hicks, Margy , Elangovan, Cheran , Romoli, Michele , Marto, João Pedro , Kasab, Sami Al

Mayo Clinic

Stroke | January 29, 2026 | Volume: 57 | Issue: Suppl_1 | Pages: No page available

10.1161/str.57.suppl_1.wp112 Get It

Background: High-grade intracranial atherosclerosis (ICAS) is associated with an elevated risk of recurrent ischemic stroke, particularly in patients with severe stenosis (70–99%). Identifying predictors of early recurrence can inform risk stratification and guide treatment strategies. Methods: The Biomarkers and Recurrence Risk in Symptomatic Intracranial Arterial Stenosis (BIORISK-ICAS) study is a multicenter, international, retrospective cohort analysis pooling data from 35 comprehensive stroke centers. We included hospitalized adult patients with symptomatic ICAS, defined as 50–99% stenosis of an intracranial artery (intracranial vertebral, basilar, distal ICA, or M1 MCA), confirmed by vascular imaging and associated with a qualifying ischemic event. Patients with only high-grade stenosis (70-99%) were included in this analysis. The primary outcome was to determine predictors of recurrent ischemic stroke in the territory of the symptomatic artery within 90 days of the index event. Baseline demographic, clinical, and imaging characteristics were recorded. Multivariable Cox proportional hazards regression with stepwise selection (p < 0.1) was used to identify independent predictors of recurrence; model discrimination was assessed using Harrell’s C-statistics. Results: Among 2,050 patients, 1,476 had high-grade (70-99%) symptomatic ICAS. The mean age was 67 ± 12.5 years, and 767 (55%) were male. Most patients were non-Hispanic (90.1%), taking dual antiplatelet therapy (77.8%), and statins (94.5%). Recurrent stroke occurred in 160 patients (10.8%) within 90 days. In multivariable Cox model, independent predictors of recurrence included atrial fibrillation (HR 2.05; 95% CI, 1.26–3.33; p = 0.004), hyperlipidemia (HR 1.57; 95% CI, 1.10–2.24; p = 0.014), diabetes mellitus (HR 1.36; 95% CI, 0.98–1.88; p = 0.064), and home use of dual antiplatelet therapy (HR 1.60; 95% CI, 1.01–2.54; p = 0.043)(Harrell’s C-statistic=0.62). In patients who underwent perfusion(n=402), mistmatch >10seconds were associated with increased recurrence (HR 1.80; 95% CI 0.95-3.38, p=0.07) and atrial fibrillation (HR 2.06: 95% CI 0.03-4.60, p=0.78) though did not reach statistical significance. Conclusion: In this population, diabetes, hyperlipidemia, atrial fibrillation, and prior use of dual antiplatelet therapy were associated with increased risk of 90-day recurrent ischemic stroke. Perfusion imaging may help identify high-risk patients who could benefit from intensified secondary prevention.
Abstract DP310: Dual Antiplatelet versus Anticoagulant-Plus-Antiplatelet Therapy in Symptomatic Intracranial Atherosclerosis: A Multicenter Comparative Study
Rehman, M. Aemaz Ur, Yaghi, Shadi, Kasab, Sami Al, Qdais, Ahmad Abu, Yaddanapudi, Sridhara , Sultana, Sabiha , Khan, Muhib, Malik, Maarij , Klaas, James P. , Guerrero, Christopher Leon, Velez, Faddi Saleh, Pinto, Camila, McCullough-Hicks, Margy, Cooper, Dawson C , Pillai, Abhiram Parameswaran, Hariharan, Praveen, Alam, Shaista , Antonenko, Kateryna, Almiri, William , Rothstein, Aaron, Krishnaiah, Balaji , Elangovan, Cheran, Agarwal, Ayush, Romoli, Michele, Nicola, Marrone, Vozzi, Stefano, Ghannam, Malik, Dibas, Mahmoud I., Marto, Joao Pedro, AlMajali, Mohammad, Sousa, Diana Aguiar de, Soares, Mafalda Delgado, Lima, Anicléia Rodrigues de, Tountopoulou, Argyro , Havenon, Adam de, Henninger, Nils, Helenius, Johanna, Khasawneh, Mohammad W , Klein, Piers, Shu, Liqi , Khatri, Pooja, Nguyen, Thanh N., Liebeskind, D, Bakradze, Ekaterina, Henninger, Nils , Sousa, Diana Aguiar de , Henninger, Nils , Aguiar de Sousa, Diana , Khan, Fahad , Yaghi, Shadi , Kasab, Sami Al , Sultana, Sabiha, Khan, Muhib , Leon Guerrero, Christopher R , Velez, Faddi G. Saleh , Owens, Cameron , Pinto, Camila, McCullough‐Hicks, Margy , Hariharan, Praveen , Alam, Shaista, Heldner, Mirjam R. , Antonenko, Kateryna , Rothstein, Aaron , Elangovan, Cheran , Romoli, Michele , Marrone, Nicola , Ghannam, Malik , Dibas, Mahmoud, Marto, João Pedro , Simpkins, Alexis N. , Soares, Mafalda , Lima, Amanda, Siegler, James E. , VASILOPOULOU, SOFIA, Klein, Piers , Bakradze, Ekaterina

Mayo Clinic

Stroke | January 29, 2026 | Volume: 57 | Issue: Suppl_1 | Pages: No page available

10.1161/str.57.suppl_1.dp310 Get It

Introduction: Intracranial atherosclerosis (ICAS) is a leading cause of ischemic stroke (IS) worldwide and carries a high risk of recurrence. Current guidelines favor 90 days of dual antiplatelet therapy (DAPT) for severe symptomatic ICAS, but recurrence remain high. Limited data suggest possible benefit of single antiplatelet plus anticoagulation (SAPT+AC). We compared the effectiveness and safety of DAPT versus SAPT+AC. We hypothesized that DAPT would lower 90-day recurrent IS risk without significantly increasing bleeding. Methods: This substudy of the Biomarkers and Recurrence Risk in Symptomatic Intracranial Arterial Stenosis (BIORISK-ICAS) included patients from 35 centers (Jan 2019–Jun 2024) with symptomatic 50–99% ICAS in the intracranial internal carotid, vertebral, basilar, or M1 segment of the MCA, presenting ≤72 hours from last known well. The primary efficacy outcome was recurrent IS in the same vascular territory at 90 days; the primary safety outcome was severe bleeding (symptomatic intracranial hemorrhage or major extracranial bleeding). Categorical variables were compared using χ 2 and continuous variables with the Student's t test; multivariable Cox regression adjusted for key covariates. Results: Of 2050 BIORISK-ICAS patients, 1658 met criteria (DAPT n=1499; SAPT+AC n=159). Mean age was 67 vs. 73 years, and 44% were women. At 90 days, recurrent IS occurred in 121 DAPT patients (8.07%) vs. 13 SAPT+AC patients (8.17%); unadjusted HR 0.83 (95% CI, 0.50–1.36; p=0.46). After adjustment for age, diabetes, coronary heart disease, atrial fibrillation, active smoking, and borderzone infarct, the adjusted HR was 0.99 (95% CI, 0.52–1.86; p=0.97). Severe bleeding occurred in 34 DAPT patients (2.26%) and 5 SAPT+AC patients (3.14%); unadjusted HR 0.79 (95% CI, 0.28–1.85; p=0.50), adjusted HR 0.66 (95% CI, 0.21–2.09; p=0.47). Conclusions: In patients with symptomatic ICAS, DAPT and SAPT+AC were associated with similar risks of 90-day recurrent ischemic stroke and severe bleeding. Well-powered randomized trials are needed to determine the optimal antithrombotic regimen in this high-risk population.
Abstract A132: Young Adults with Cervical Artery Dissection have a Distinct Clinical Phenotype: A Post-Hoc Analysis of the STOP-CAD Study
Omran, Setareh Salehi , Shu, Liqi , Yaghi, Shadi, Sidebottom, Christian, Crandall, Ross , Lester, Evan, Lee, Conner, Henninger, Nils, Antonenko, Kateryna, Khan, Muhib, Mallick, Dania, Rothstein, Aaron, Khazaal, Ossama , Engelter, Stefan T, Traenka, Christopher , Gandhi, Preet , Metanis, Issa, Leker, Ronen, Guo, Xiaofan, Ghannam, Malik, AlMajali, Mohammad, Samaniego, Edgar, Fonseca, Ana, Cruz, Diana, Romoli, Michele, Keser, Zafer, Zedde, Marialuisa, Bakradze, Ekaterina, Velez, Faddi Saleh, Penckofer, Mary , Zubair, Adeel , Marto, Joao Pedro, Klein, Piers, Nguyen, Thanh N., Khasiyev, Farid, Elnazeir, Marwa , Krishnaiah, Balaji , Elangovan, Cheran, Henninger, Nils , Henninger, Nils , Yaghi, Shadi , Muppa, Jayachandra , Gunduz, Muhammed Enes , Heldner, Mirjam R. , Antonenko, Kateryna , Nehme, Ahmad , Khan, Muhib , Rothstein, Aaron , Kaufmann, Josefin E. , Engelter, Stefan T. , Metanis, Issa , Leker, Ronen R , von Rennenberg, Regina , Shahripour, Reza Bavarsad , Ghannam, Malik , Cruz, Diana , Romoli, Michele , Keser, Zafer , Zedde, Marialuisa , Grory, Brian Mac , Bakradze, Ekaterina , Velez, Faddi G. Saleh , Siegler, James E. , Willey, Joshua , Marto, João Pedro , Klein, Piers , Nguyen, Thanh N. , Simpkins, Alexis N. , Elangovan, Cheran

Mayo Clinic

Stroke | January 29, 2026 | Volume: 57 | Issue: Suppl_1 | Pages: No page available

10.1161/str.57.suppl_1.a132 Get It

Background and Objectives: Cervical artery dissection (CeAD) is a common cause of ischemic stroke in young adults. We aim to identify age-based differences in clinical presentation, imaging findings, and outcomes after CeAD. Methods: This was a sub-study using the STOP-CAD registry, a multicenter cross-sectional international retrospective study of patients diagnosed with CeAD and treated with an antithrombotic from January 1, 2015 to December 31, 2021. Baseline clinical and imaging characteristics were compared between younger and older adults with CeAD (≤45 versus >45 years of age) using multivariable logistic regression. We chose this age cut off due to its frequent usage in stroke in the young literature. Multiple logistic regression models were used to determine association between young age and outcomes after CeAD (ischemic stroke at 180 days, excellent functional outcome with modified Rankin Scale of 0-1 at 90 days, and mortality) after adjusting for sex, vascular risk factors, CeAD characteristics, and NIHSS on presentation. Results: Among 4023 CeAD patients included in the study, 1901 (47.3%) were ≤45 years of age. Patients were followed for a median of 307 days (IQR 102-831). Young adults with CeAD were more likely to be women (Odds Ratio [OR], 2.4; 95% CI, 2.1-2.9; p<0.001), of Hispanic ethnicity (OR, 1.8; 95% CI 1.3-2.5; p<0.001), have a history of migraines (OR, 1.6; 95% CI, 1.3-2.0; p<0.001) and recent neck trauma (OR, 1.6; 95% CI, 1.3-1.9; p<0.001) while having fewer traditional vascular risk factors. Young adults with CeAD had higher odds of a non-ischemic presentation (OR, 1.3; 95% CI, 1.1-1.5; p=0.013), vertebral artery dissection (OR 2.5; 95% CI, 2.2-3.0; p<0.001), and multivessel involvement (OR 1.5; 95% CI, 1.1-1.9; p=0.004). In adjusted analysis, younger age was not associated with an increased risk of recurrent ischemic stroke (adjusted Hazard Ratio [HR], 0.48; 95% CI 0.2-1.2; p=0.119). Younger age was associated with significantly greater odds of excellent functional outcome at 90 days (aOR, 1.48; 1.20-1.84, p<0.001) and lower risk of death at follow up (aHR, 0.37; 95% CI, 0.17-0.81; p=0.012) after CeAD. Conclusion: In a large international cohort, young adults with CeAD had a distinct clinical phenotype with higher odds of non-ischemic presentation, vertebral artery dissection, and multivessel involvement while having fewer traditional vascular risk factors. Young adults had a decreased odds of disability and mortality after CeAD.
Dissecting Aneurysm in Cervical Artery Dissection: Insights From the STOP-CAD Study
Khan, Muhib, Keser, Z, Shu, Liqi , Lee, Elizabeth M., Ho, Melanie, Klein, Piers, Mallick, Dania, Griffin, Kim, Mandel, Daniel M, Leker, Ronen R., Metanis, Issa, Krishnaiah, Balaji , Omran, Setareh Salehi , Bakradze, Ekaterina, Henninger, Nils, Engelter, Stefan T, Antonenko, Kateryna, Marto, Joao Pedro, Rothstein, Aaron, Khazaal, Ossama , Nolte, Christian H., Crandall, Ross Curtiss, Lester, Evan, Nehme, Ahmad , Ghannam, Malik, AlMajali, Mohammad, Elnazeir, Marwa , Kasab, Sami Al, Asad, Syed Daniyal , Balabhadra, Anvesh , Fonseca, Ana Catarina , Cruz, Diana , Romoli, Michele, Sen, Shayak, Zedde, Marialuisa, Samaniego, Edgar A., Zubair, Adeel , Stretz, Christoph, Kam, Wayneho , AbdalKader, Mohamad, Yaghi, Shadi, Nguyen, Thanh N., Keser, Zafer , Klein, Piers , Henninger, Nils , Mandel, Daniel , Lee, Elizabeth , Nolte, Christian H. , Khan, Muhib , Keser, Zafer , Lee, Elizabeth , Klein, Piers , Griffin, Kim J. , Mandel, Daniel M , Leker, Ronen R , Metanis, Issa , Salehi Omran, Setareh , Bakradze, Ekaterina , Henninger, Nils , Engelter, Stefan T , Heldner, Mirjam R , Antonenko, Kateryna , Siegler, James E , Marto, João Pedro , Rothstein, Aaron , Khazaal, Ossama , Nolte, Christian H , Crandall, Ross , Nehme, Ahmad , Mac Grory, Brian , Ghannam, Malik , Almajali, Mohammad , Elnazeir, Marwa , Al Kasab, Sami , Asad, Syed Daniyal , Balabhadra, Anvesh , Fonseca, Ana Catarina , Cruz, Diana , Romoli, Michele , Saleh Velez, Faddi , Simpkins, Alexis N , Zedde, Marialuisa , Samaniego, Edgar A , Zubair, Adeel , Stretz, Christoph , Kam, Wayneho , Abdalkader, Mohamad , Yaghi, Shadi , Nguyen, Thanh N , Khan, Muhib , Ho, Melanie, Metanis, Issa , Shahripour, Reza Bavarsad , Bakradze, Ekaterina , Engelter, Stefan T. , Heldner, Mirjam R. , Siegler, James E. , Marto, João Pedro , Rothstein, Aaron , Crandall, Ross , Grory, Brian Mac , Ghannam, Malik , Kasab, Sami Al , Velez, Faddi G. Saleh , Simpkins, Alexis N. , Zedde, Marialuisa , Stretz, Christoph , Abdalkader, Mohamad , Yaghi, Shadi

Mayo Clinic

Stroke | January 29, 2026 | Volume: 57 | Issue: 4 | Pages: 865-875

10.1161/strokeaha.125.054847 | PMID 41608793 Get It

BACKGROUND: Cervical artery dissection (CeAD) may result in dissecting aneurysm (DA) formation. We aimed to characterize risk factors and clinical outcomes associated with DA in a large, international CeAD cohort. METHODS: We performed a secondary analysis of STOP-CAD (Antithrombotic Treatment for Stroke Prevention in Cervical Artery Dissection), an international, multicenter, retrospective cohort. Patients with spontaneous CeAD were assessed for DA at baseline and de novo DA formation. Significant covariates in univariable analysis were included in multivariable regression models aiming to identify factors associated with DA formation. Logistic regression and Cox proportional hazards models evaluated the association of DA with ischemic and hemorrhagic outcomes. RESULTS: Among 4008 patients with CeAD, 546 (13.6%) had a DA at baseline, and 221/2938 (7.5%) patients developed a de novo DA during follow-up, of which 172/221 (78.2%) were detected in the first 180 days. Patients with DA had a mean age of 47 years, and 383 (49.9%) were women. Baseline or de novo DA was associated with a history of connective tissue disorder (adjusted odds ratio [aOR], 2.02 [95% CI, 1.22–3.36]), fibromuscular dysplasia (aOR, 1.69 [95% CI, 1.28–2.25]), and multiple vessel dissection (aOR, 1.53 [95% CI, 1.19–1.98]). Lower odds of DA were seen in Hispanic ethnicity (aOR, 0.64 [95% CI, 0.43–0.97]) and ischemic stroke presentation (aOR, 0.41 [95% CI, 0.34–0.49]). Fibromuscular dysplasia was associated with de novo DA formation (aOR, 2.30 [95% CI, 1.52–3.49]). DA was not associated with ischemic stroke (hazard ratio, 0.71 [95% CI, 0.44–1.16]; P =0.173) or intracranial hemorrhage (HR, 1.09 [95% CI, 0.42–2.84]; P =0.86) by day 180. CONCLUSIONS: DAs are relatively common manifestations of CeAD, typically occurring within 6 months of CeAD diagnosis. DA was not associated with an increased risk of subsequent ischemic stroke or intracranial hemorrhage.
Palopegteriparatide for adults with chronic hypoparathyroidism: skeletal dynamics through 3 years of the phase 2 PaTH forward trial
Rubin, Mishaela R. , Clarke, B.L. , Khan, Aliya, Schwarz, Peter, Vokes, Tamara , Ahmed, Intekhab, Palermo, Andrea, Cetani, F., Pagotto, Uberto , Zhao, Carol, Ominsky, Michael S. , Lai, Bryant, Ukena, Jenny, Shu, Aimee D , Rejnmark, L, Schwarz, Peter , Palermo, Andrea , Clarke, Bart L , Khan, Aliya A , Schwarz, Peter , Palermo, Andrea , Cetani, Filomena , Pagotto, Uberto , Shu, Aimee D , Rejnmark, Lars , Hofbauer, Lorenz C. , Khan, Aliya , Zhao, Carol, Ukena, Jenny, Rejnmark, Lars

Mayo Clinic

Journal of Bone and Mineral Research | January 22, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/jbmr/zjag013 | PMID 41636590 Get It

Abstract Hypoparathyroidism is an endocrine disease caused by insufficient levels of PTH, which acts directly on bone and kidney and indirectly on the intestine to regulate calcium and phosphate balance. In clinical trials, palopegteriparatide (TransCon PTH) treatment enabled independence from conventional therapy (no active vitamin D, ≤600 mg/d calcium) and maintained serum biochemistries within normal ranges. The current analyses describe patterns of change in BMD, serum bone turnover markers, and serum and urine calcium in adults with chronic hypoparathyroidism treated with palopegteriparatide through 3 years of the PaTH Forward trial. Baseline BMD Z-scores for the LS, TH, FN, and 1/3 distal radius were above zero, indicating bone mass exceeding age-adjusted normative values. BMD decreased from these elevated baseline levels with palopegteriparatide treatment, with larger reductions during the first 26 weeks and modest declines thereafter. Mean BMD Z-scores at week 162 remained above zero for all 4 sites. Participants with lower baseline BMD (Z-scores below −1 and T-scores below −2.5) generally exhibited lesser declines in BMD versus those with higher baseline BMD. Palopegteriparatide treatment was associated with early increases in bone resorption (serum C-terminal telopeptide of type I collagen, CTx) and bone formation (serum procollagen type 1 N-terminal propeptide, P1NP) that peaked at weeks 12 and 26, respectively, followed by declines to levels moderately higher than baseline at week 162. Mean CTx and P1NP in the overall population and the subgroup of postmenopausal women were below their upper limits of normal from weeks 58-162. At week 162, mean serum and median urine calcium remained within normal ranges and 91% of participants were independent from conventional therapy. These results suggest that long-term palopegteriparatide therapy in adults with chronic hypoparathyroidism gradually returns the skeleton toward its natural state thereby enhancing the skeleton’s contribution to calcium homeostasis.
Characteristics of patients with extracranial cervical artery dissections involving more than a single vessels: A subgroup analysis of STOP-CAD
Metanis, Issa, Akpokiere, Favour , Shu, Liqi , Jubran, Hamza , Antonenko, Kateryna, Rosa, Sara, Soares, Mafalda Delgado, Engelter, Stefan T. , Traenka, Christopher Kenan, Marto, João Pedro, Romoli, Michele, Zubair, Adeel , Omran, Setareh Salehi , Jubeh, Tamer , Shalabi, Fatma , Khan, Muhib, DeSousa, Diana Aguiar, Yaghi, Shadi, Leker, Ronen R., Sousa, Diana Aguiar de , Soares, Mafalda , Rosa, Sara , Jubran, Hamza , Engelter, Stefan T , Kaufman, Josefin E , Marto, João Pedro , Keser, Zafer , Aguiar de Sousa, Diana , Leker, Ronen R , Soares, Mafalda , Rosa, Sara , Metanis, Issa , Schwartzmann, Yoel , Antonenko, Kateryna , Heldner, Mirjam R. , Kaufmann, Josefin E. , Romoli, Michele , Keser, Zafer , Khan, Muhib , Yaghi, Shadi

Mayo Clinic

European Stroke Journal | January 20, 2026 | Volume: 11 | Issue: 1 | Pages: No page available

10.1093/esj/23969873251383313 | PMID 41614464 Get It

Abstract Introduction Cervical arterial dissections (CeAD) can involve either single (sCeAD) or multiple (mCeAD) arteries. Whether the involvement of a single versus multiple arteries is associated with outcomes remains unclear. We aimed to study associations between the number of affected arteries and clinical, imaging and outcome parameters. Patients and methods Patients with CeAD from the STOP-CAD multicenter registry study were included. Clinical, imaging, treatment and outcome parameters were compared between patients with sCeAD and mCeAD. Regression analyses were performed to identify associations with multi-arteries involvement. Results Overall, 3858 STOP-CAD patients were included in this analysis and 443 (11.5%) had mCeAD. The presence of mCeAD was associated with age (adjusted odds ratio [aOR] 95% confidence intervals [95% CI] 0.99; (0.98–1.00)), female sex (aOR 1.5; 95% CI 1.17–1.91), recent upper respiratory infection (aOR 2.25; 95% CI 1.55–3.27), presence of connective tissue disease (aOR 3.11; 95% CI 2.32–4.17), severe arterial stenosis (aOR 1.95; 95% CI 1.95–2.58), intracranial extension (aOR 1.47; 95% CI 1.04–2.09), vertebral artery involvement (aOR 2.50; 95% CI 1.94–3.22) and presence of dissecting aneurysm (aOR 2.59; 95% CI 1.95–3.42). In adjusted analyses, mCeAD was not associated with clinical outcomes (ischemic stroke, mortality, and sICH; all p &gt; 0.05). Conclusions mCeAD does not appear to increase risk of subsequent stroke as compared to sCAD despite baseline risk factors suggestive of vasculopathy. mCeAD patients who did develop a stroke presented with milder strokes and less often had vessel occlusions compared to those with sCeAD. The presence of mCeAD did not impact outcomes.
Single-arm phase 2 study of the FGFR inhibitor futibatinib (Futi) in combination with pembrolizumab (Pem) in patients with FGF19 expressing advanced or metastatic hepatocellular carcinoma (aHCC).
Palmer, Mathias Earl, Ulrich, Angela, Babiker, Hani M., Revzin, Alexander , Gores, Gregory J., Jin, Zhaohui, Fonkoua, Lionel Aurelien Kankeu, Roberts, Lewis R. , Goenka, Ajit H. , Mahipal, A., Tran, Nguyen H., Roberts, Lewis R , Wee, Wen , Bekaii‐Saab, Tanios , Borad, Mitesh J. , Babiker, Hani M. , Majeed, Umair , Gores, Gregory J. , Hálfdánarson, Þorvarður R. , Jin, Zhaohui , Fonkoua, Lionel Aurelien Kankeu , McWilliams, Robert R. , Graham, Rondell P. , Heimbach, Julie K. , Mahipal, Amit , Ou, Fang‐Shu , Tran, Nguyen H.

Mayo Clinic

Journal of Clinical Oncology | January 12, 2026 | Volume: 44 | Issue: 2_suppl | Pages: 561-561

10.1200/jco.2026.44.2_suppl.561 Get It

561 Background: For patients with aHCC, second-line treatment options are not well established. The primary aim of this study was to evaluate the efficacy of Futi, an FGFR 1-4 inhibitor, in combination with Pem as a second line therapy in patients with FGF19-expressing aHCC. Methods: Patients aged ≥ 18 years, with histological/cytological diagnosis or radiological diagnosis of HCC, Child-Pugh (CP) class A-B7, Barcelona Clinic Liver Cancer (BCLC) A, B or C, ECOG performance status of 0-2, and FGF19+, by in-situ hybridization or immunohistochemistry, received Futi 20 mg once daily plus i.v. Pem 200mg every 3 weeks. The primary endpoint was progression-free survival at 6 months (PFS6). Secondary endpoints include overall survival (OS). The study was designed to enroll 22 evaluable patients to detect PFS6 from 25% (historical control) to 47%, assuming a 1-sided alpha of 0.1 with 80% power. All patients provided written consent. Eligible patients with consent who started treatment are considered evaluable. Results: The study was closed to enrollment early at the request of funding agency due to poor accrual. Between 8/2021 and 3/2024, 14 patients enrolled with 1 patient withdrawing consent before beginning protocol treatment. Among 13 evaluable patients, median age was 72 (range: 60-87) years, 7 (53.8%) were male, 12 CP A (92.3%), 7 BCLC C (53.8%), with 7 (53.8%) having received prior liver directed therapy. Median PFS was 15 weeks (95% confidence interval [CI]: 9.0-Not Estimable) and PFS6 was 23.1% (95% CI: 8.6%, 62.3%). Objective response rate was 0% (95% CI: 0%, 24.71%) and stable disease occurred in 7 (53.9%) of patients. Median OS was 55.7 weeks (95% CI: 47.3-NE). Nine (69.2%) patients experienced at least 1 grade 3+ adverse event (AE), and 2 (15.4%) patients experienced at least a grade 4+ AE. One patient had a grade 5 AE unrelated to study treatment (acute kidney injury). Most commonly reported AEs (occurring in more than 31% of patients) were hyperphosphatemia (76.9%), fatigue (69.3%), diarrhea (61.6%), AST (53.9%) and ALT (46.2%), dry eye (38.5%), nail changes (38.5%), rash-maculo-papular (38.5%), and mucositis oral (38.5%). Conclusions: This prospective study evaluated the use of a targeted treatment in combination with immunotherapy following first line immune-based therapy. This combination had modest activity as a second line therapy for patients with aHCC but did not meet the primary endpoint. The safety profile was acceptable and consistent with prior reports. An optimal second-line regimen remains a critical need. Clinical trial information: NCT04828486 .
A phase II randomized study of atezolizumab plus multikinase inhibitor (MKI) versus MKI alone in patients with advanced hepatocellular carcinoma previously treated with atezolizumab plus bevacizumab (Atezo/Bev).
Nelson, Garth, Tran, Nguyen H., Crysler, Oxana , Iyer, R. Rajagopalan , Morse, M., Washburn, Leslie, Fonkoua, Lionel Aurelien Kankeu, Fountzilas, C., Peersen, Anina, Sahai, Vaibhav , Mohan, Arathi , Sahai, Vaibhav , Wee, Wen , Nelson, Garth D., Tran, Nguyen H. , Morse, Michael M., Fonkoua, Lionel Aurelien Kankeu , Fountzilas, Christos , Sonbol, Mohamad Bassam , Ou, Fang‐Shu , Bekaii‐Saab, Tanios

Mayo Clinic

Journal of Clinical Oncology | January 12, 2026 | Volume: 44 | Issue: 2_suppl | Pages: 554-554

10.1200/jco.2026.44.2_suppl.554 Get It

554 Background: Atezo/Bev is the 1 st -line standard for advanced hepatocellular carcinoma (aHCC). Optimal 2 nd -line therapy post-Atezo/Bev remains undefined. This study evaluates continuation of atezolizumab with a MKI versus MKI alone in the 2 nd -line setting. Methods: This multicenter, randomized phase II trial enrolled patients with unresectable aHCC who progressed on Atezo/Bev. Patients were randomized 2:1 to atezolizumab plus MKI (cabozantinib or lenvatinib; Arm A) or MKI alone (Arm B). Stratification factors included MKI choice, viral etiology, and alpha-fetoprotein levels. Dual primary endpoints were overall survival (OS) and progression-free survival (PFS). Secondary endpoints included objective response rate (ORR), duration of response (DOR), and safety. With 84 death and 89 PFS events, from 122 patients, this trial had 80% power to detect a hazard ratio (HR) of 0.556 in OS and HR of 0.571 in PFS with a one-sided type I error (alpha) of 0.05 for each endpoint. Results: Twenty patients were accrued across 5 U.S. centers, between 01/2022 and 03/2025, before early closure due to slow accrual. Eighteen received treatment (Arm A: n=13; Arm B: n=5). Baseline characteristics: median age 68 yr, extrahepatic 56%, Hep B+ 0%, Hep C+ 33%, NASH 33% and CP A (5 to 6) 100%. MKIs used were cabozantinib (Arm A: 6/13; Arm B: 4/5) and lenvatinib (Arm A: 7/13; Arm B: 1/5). Median follow-up was 28.0 months (mo), with 14 deaths reported. Median (95% CI) OS were 13.9 (7.1-Not Estimable [NE]) and 6.2 (5.1-NE) mo (Arm A and B respectively); and that of PFS 4.3 (2.3-NE) and 4.1 (3.7-NE) mo. ORR was 7.7% (1/13) in Arm A (responder received lenvatinib) and 0% (0/5) in Arm B. Grade ≥3 adverse events (at least possibly related) occurred in 46.2% of Arm A and 60.0% of Arm B patients. G3+ events occurring in >10% of patients included hypertension, fatigue, anorexia, and ALT elevation in Arm A; and hypertension, hallucination, nausea, hypomagnesemia, hypokalemia, mucositis, AST increased and colitis in Arm B. Conclusions: In this limited cohort, continuation of atezolizumab with MKI showed relative activity and manageable safety in aHCC post-Atezo/Bev. The AE profile for atezo/MKI is consistent with the known profile of respective agents. These findings support further investigation of immunotherapy-based combinations in the 2nd-line setting. Clinical trial information: NCT05168163 .
ACCRU-GI-1810: Trifluridine/tipiracil (FTD-TPI) or paclitaxel (PAC) in combination with ramucirumab (RAM) for patients (pts) with previously treated advanced gastroesophageal adenocarcinoma (GEA)—An investigator-initiated, randomized non-inferiority phase
Peersen, Anina, Ahn, D., Starr, Jason S., Jaslowski, Anthony J., Nagarajan, Arun , Iqbal, S. , Gibson, Michael K., Bekaii-Saab, Tanios S., Sonbol, Mohamad Bassam , Ulrich, Angela, Ou, Fang‐Shu , Starr, Jason S. , Bekaii‐Saab, Tanios

Mayo Clinic

Journal of Clinical Oncology | January 12, 2026 | Volume: 44 | Issue: 2_suppl | Pages: 392-392

10.1200/jco.2026.44.2_suppl.392 Get It

392 Background: PAC+RAM is the standard second-line therapy for advanced GEA. However, PAC-related neuropathy is a major challenge, particularly since many pts have pre-existing neuropathy from prior platinum exposure. An effective “neuropathy-free” regimen remains an unmet need. We evaluated FTD-TPI+RAM as an alternative to PAC+RAM. Methods: This multi-center, randomized, phase II study enrolled GEA pts who progressed on or were intolerant to fluoropyrimidine+ platinum therapy. Pts were randomized to FTD-TPI+RAM (Arm A) or PAC+RAM (arm B) at a 1:1 ratio. The primary endpoint was progression-free survival (PFS), defined as time interval between randomization date and the date of disease progression or death; Secondary endpoints included overall survival (OS) and adverse events (AEs). The design hypothesized non-inferiority (NI) of Arm A to Arm B with a NI margin of hazard ratio 1.19. 90 PFS events from 116 pts provide 80% power with a one-sided alpha of 0.15. The interim futility analysis, conducted in December 2024 with 20 events, did not cross the futility boundary (Z statistic ≥ 1.172 ) and continued enrolling pts. The trial closed enrollment in March 2025 due to slow accrual. At the time of interim analysis, 20 events had occurred and the Z statistic was 0.4532. Final analysis included the 29 pts that were eligible, consented, randomized, and received any protocol treatment. Results: Among 29 pts (15 Arm A; 14 Arm B), baseline characteristics were balanced (in Arms A vs B, median age 64 vs 63; 80% vs 85.7% male; 86.7%% vs 78.6% White; 80% vs 78.6% ECOG 1). At data freeze of 8/4/2025, 26 PFS events were reported. Median PFS was 3.2 vs. 3.9 months in Arm A vs. Arm B (HR 1.37, 95% CI 0.61-3.02). NI was not demonstrated (Z =0.34, threshold for NI<-1.036). Median OS was 8.4 vs. 10.7 months, in Arms A and B, respectively. Grade ≥3 AEs occurred in 93% (Arm A) vs 71% (Arm B) with hematologic AEs occurring more frequently in Arm A than Arm B (53% vs 29%). Peripheral sensory neuropathy (any grade) occurred more frequently in Arm B (86%) vs. Arm A (47%). Conclusions: Although NI was not achieved due to early closure and small sample size, FTD-TPI+RAM was relatively safe and associated with less neuropathy compared with PAC+RAM. This regimen warrants further evaluation for pts in whom neuropathy limits taxane use. Clinical trial information: NCT04660760 .
Indian Hedgehog expression and association with cetuximab benefit in metastatic colorectal cancer (mCRC): Evidence from CALGB (Alliance)/SWOG 80405.
Bartolini, Michela, Yang, Yan , Millstein, Joshua , Soni, Sneha, Mittal, Pooja, Algaze, Sandra, Shah, Unnati Hemant, Torres-Gonzalez, Lesly, Zhang, Wu , Venook, Alan P., Innocenti, Federico , Lenz, Heinz-Josef, Torres‐Gonzalez, Lesly , Yang, Yan, Ou, Fang‐Shu , Battaglin, Francesca , Mittal, Pooja , Algaze, Sandra , Venook, Alan P. , Puccini, Alberto , Lenz, Heinz‐Josef

Mayo Clinic

Journal of Clinical Oncology | January 12, 2026 | Volume: 44 | Issue: 2_suppl | Pages: 198-198

10.1200/jco.2026.44.2_suppl.198 Get It

198 Background: The Hedgehog (Hh) signaling pathway regulates tissue patterning, growth and differentiation, including within gastrointestinal tract. Mammalian homologs include Sonic (SHH), Indian (IHH) and Desert (DHH) Hedgehog, which signal through PTCH and SMO and the GLI transcription factors. In the digestive tract, both SHH and IHH are expressed, but the functional role of Hh signaling in mCRC remains incompletely defined. Methods: We analyzed 433 mCRC patients treated with either bevacizumab (bev = 226) or cetuximab (cet = 207) plus first line chemotherapy in CALGB/SWOG 80405 (NCT00265850). RNA expression (Illumina HiSeq 2500) of 9 Hh pathway genes (SHH, IHH, DHH, PTCH1, PTCH2, SMO, GLI1, GLI2, GLI3) was evaluated. Median overall survival (mOS) and progression free survival (mPFS) in months (mo) were compared across expression tertiles (low [L], medium [M], high [H]). Likelihood ratio tests, hazard ratios and 95% confidence intervals were computed from multivariable Cox proportional hazards models, adjusting for age, sex, ethnicity, ECOG PS, tumor location, number of metastatic sites, KRAS , microsatellites instability status and treatment. Prognostic effects were modeled as marginal terms; predictive effects were modeled as multiplicative interactions. Results: Overall, IHH and GLI2 demonstrated prognostic value for OS after adjusting for multiple testing (Benjamini-Hochberg False Discovery Rate (FDR) < 0.05). High IHH expression (H group, n = 143) correlated with improved mOS (H: 36.0 mo vs M: 32.8 mo vs L: 23.5 mo; p= 0.031), whereas low GLI2 expression (L group, n = 145) was associated with longer mOS (H: 25.6 mo vs M: 33.9 mo vs L: 33.7 mo; p= 0.0016). Moreover, IHH showed predictive value for cet benefit in both OS (mOS H: 38.1 mo vs M: 34.0 mo vs L: 18.4 mo; p= 0.0032) and PFS (mPFS H: 12.6 mo vs M: 12.9 mo vs L: 8.8 mo; p= 0.0025) with significant treatment interaction for OS and PFS (p= 0.0046 and p= 0.0049, respectively; FDR< 0.05). No significant associations were found in bev treated pts. No other Hh genes showed significant prognostic or predictive effects after FDR correction. Conclusions: These results highlight a dual role of Hh pathway in mCRC. Consistent with prior preclinical evidence, reduced IHH expression appears to mark poor prognosis, likely reflecting the loss of IHH-mediated restraint on Wnt signaling, which drives proliferation and dedifferentiation. Conversely, low GLI2, a downstream transcription factor, was linked with favorable outcomes, underscoring context-specific effects of Hh signaling. The strong predictive association of IHH with cet efficacy supports its potential as a biomarker in RAS wild type mCRC. These results suggest that Hh pathway modulation, particularly IHH signaling, may influence disease biology and treatment response. Validation in independent cohorts and mechanistic studies is warranted to clarify implications.